Evidence map›Paper›PMID 41169336›Full record

ArticleChina CDC weekly2025

Evaluation of Measles Vaccine Immunogenicity and Durability Using A Pseudotyped Virus Neutralization Assay.

Qi Jiang, Xi Wu, Jie Zhang, Huiling Wang, Fangyu Dong, Xuelian Wu, Pengju Yu, Jianhui Nie, Youchun Wang, Weijin Huang and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in China CDC weekly, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Qi JiangDivision of HIV/AIDS and Sexually Transmitted Virus Vaccines, Institute for Biological Product Control, State Key Laboratory of Drug Regulatory Science, National Institutes for Food and Drug Control (NIFDC), Beijing, China.
Xi WuDivision of HIV/AIDS and Sexually Transmitted Virus Vaccines, Institute for Biological Product Control, State Key Laboratory of Drug Regulatory Science, National Institutes for Food and Drug Control (NIFDC), Beijing, China.
Jie ZhangDivision of HIV/AIDS and Sexually Transmitted Virus Vaccines, Institute for Biological Product Control, State Key Laboratory of Drug Regulatory Science, National Institutes for Food and Drug Control (NIFDC), Beijing, China.
Huiling WangWHO Western Pacific Regional Measles/Rubella Reference Laboratory, National Key Laboratory for Intelligent Tracking and Forecasting of Infectious Diseases, NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Fangyu DongDepartment of Research & Development, Taibang Biologics Group, Beijing, China.
Xuelian WuDivision of HIV/AIDS and Sexually Transmitted Virus Vaccines, Institute for Biological Product Control, State Key Laboratory of Drug Regulatory Science, National Institutes for Food and Drug Control (NIFDC), Beijing, China.
Pengju YuDivision of HIV/AIDS and Sexually Transmitted Virus Vaccines, Institute for Biological Product Control, State Key Laboratory of Drug Regulatory Science, National Institutes for Food and Drug Control (NIFDC), Beijing, China.
Jianhui NieDivision of HIV/AIDS and Sexually Transmitted Virus Vaccines, Institute for Biological Product Control, State Key Laboratory of Drug Regulatory Science, National Institutes for Food and Drug Control (NIFDC), Beijing, China.
Youchun WangInstitute of Medical Biology, Chinese Academy of Medical Sciences, Kunming City, Yunnan Province, China.
Weijin HuangDivision of HIV/AIDS and Sexually Transmitted Virus Vaccines, Institute for Biological Product Control, State Key Laboratory of Drug Regulatory Science, National Institutes for Food and Drug Control (NIFDC), Beijing, China.
Jiuyue ZhouDepartment of Research & Development, Taibang Biologics Group, Beijing, China.
Yaru QuanDivision of Respiratory Virus Vaccines, National Institutes for Food and Drug Control, Beijing, China.
Yan ZhangWHO Western Pacific Regional Measles/Rubella Reference Laboratory, National Key Laboratory for Intelligent Tracking and Forecasting of Infectious Diseases, NHC Key Laboratory of Medical Virology and Viral Diseases, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Suting WangShandong Center for Disease Control and Prevention, Jinan City, Shandong Province, China.
Juan LiDivision of Respiratory Virus Vaccines, National Institutes for Food and Drug Control, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: This study aimed to establish a robust method for monitoring measles vaccine-induced immunity and assessing population-level serostatus. Methods: This study constructed a vesicular stomatitis virus (VSV)-based pseudotyped virus system expressing envelope proteins from seven major circulating measles genotypes (H1, B3, D4, D8, D9, D11, G3) and the Schwarz vaccine strain (genotype A), thereby enabling a high-throughput neutralization assay for antibody detection. Results: Vaccination induced a substantial increase in neutralizing antibody geometric mean titers (GMT) post-immunization (4,808 after the first dose; 5,326 after the second dose), with antibody levels remaining elevated in 4-year-old children (GMT: 3,834). Cross-neutralization activity against different genotypes varied by less than 6.4-fold, demonstrating broad protective immunity. However, 12% of adult sera tested were seronegative, revealing the presence of susceptible populations. Conclusions: This study confirms the robust immunogenicity of the current measles vaccine and establishes a valuable tool for serosurveillance and long-term immunity assessment.

Indexed as

F proteinH proteinMeasles virusPseudotyped virus

Identifiers

PMID41169336
PMCPMC12569535

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.